Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2

Donald S. McCorquodale, Gladys Montenegro, Ainsley Peguero, Nicole Carlson, Fiorella Speziani, Justin Price, Sean W. Taylor, Michel Melanson, Jeffery M Vance, Stephan L Zuchner

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Charcot-Marie-Tooth (CMT) disease is among the most common inherited neurological disorders. Mutations in the gene mitofusin 2 (MFN2) cause the axonal subtype CMT2A, which has also been shown to be associated with optic atrophy, clinical signs of first motor neuron involvement, and early onset stroke. Mutations in MFN2 account for up to 20-30% of all axonal CMT type 2 cases. To further investigate the prevalence of MFN2 mutations and to add to the genotypic spectrum, we sequenced all exons of MFN2 in a cohort of 39 CMT2 patients. We identified seven variants, four of which are novel. One previously described change was co-inherited with a PMP22 duplication, which itself causes the demyelinating form CMT1A. Another mutation was a novel in frame deletion, which is a rare occurrence in the genotypic spectrum of MFN2 characterized mainly by missense mutations. Our results confirm a MFN2 mutation rate of ~15-20% in CMT2.

Original languageEnglish
Pages (from-to)1234-1239
Number of pages6
JournalJournal of Neurology
Volume258
Issue number7
DOIs
StatePublished - Jul 1 2011

Fingerprint

Charcot-Marie-Tooth Disease
Mutation
Optic Atrophy
Motor Neurons
Mutation Rate
Missense Mutation
Nervous System Diseases
Exons
Tooth
Stroke
Genes

Keywords

  • Charcot-Marie-Tooth disease
  • CMT2
  • CMT2A
  • Inherited peripheral neuropathies
  • MFN2
  • Mitofusin 2

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

McCorquodale, D. S., Montenegro, G., Peguero, A., Carlson, N., Speziani, F., Price, J., ... Zuchner, S. L. (2011). Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2. Journal of Neurology, 258(7), 1234-1239. https://doi.org/10.1007/s00415-011-5910-7

Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2. / McCorquodale, Donald S.; Montenegro, Gladys; Peguero, Ainsley; Carlson, Nicole; Speziani, Fiorella; Price, Justin; Taylor, Sean W.; Melanson, Michel; Vance, Jeffery M; Zuchner, Stephan L.

In: Journal of Neurology, Vol. 258, No. 7, 01.07.2011, p. 1234-1239.

Research output: Contribution to journalArticle

McCorquodale, DS, Montenegro, G, Peguero, A, Carlson, N, Speziani, F, Price, J, Taylor, SW, Melanson, M, Vance, JM & Zuchner, SL 2011, 'Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2', Journal of Neurology, vol. 258, no. 7, pp. 1234-1239. https://doi.org/10.1007/s00415-011-5910-7
McCorquodale DS, Montenegro G, Peguero A, Carlson N, Speziani F, Price J et al. Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2. Journal of Neurology. 2011 Jul 1;258(7):1234-1239. https://doi.org/10.1007/s00415-011-5910-7
McCorquodale, Donald S. ; Montenegro, Gladys ; Peguero, Ainsley ; Carlson, Nicole ; Speziani, Fiorella ; Price, Justin ; Taylor, Sean W. ; Melanson, Michel ; Vance, Jeffery M ; Zuchner, Stephan L. / Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2. In: Journal of Neurology. 2011 ; Vol. 258, No. 7. pp. 1234-1239.
@article{049595e8da5a4aff959b4495a223d015,
title = "Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2",
abstract = "Charcot-Marie-Tooth (CMT) disease is among the most common inherited neurological disorders. Mutations in the gene mitofusin 2 (MFN2) cause the axonal subtype CMT2A, which has also been shown to be associated with optic atrophy, clinical signs of first motor neuron involvement, and early onset stroke. Mutations in MFN2 account for up to 20-30{\%} of all axonal CMT type 2 cases. To further investigate the prevalence of MFN2 mutations and to add to the genotypic spectrum, we sequenced all exons of MFN2 in a cohort of 39 CMT2 patients. We identified seven variants, four of which are novel. One previously described change was co-inherited with a PMP22 duplication, which itself causes the demyelinating form CMT1A. Another mutation was a novel in frame deletion, which is a rare occurrence in the genotypic spectrum of MFN2 characterized mainly by missense mutations. Our results confirm a MFN2 mutation rate of ~15-20{\%} in CMT2.",
keywords = "Charcot-Marie-Tooth disease, CMT2, CMT2A, Inherited peripheral neuropathies, MFN2, Mitofusin 2",
author = "McCorquodale, {Donald S.} and Gladys Montenegro and Ainsley Peguero and Nicole Carlson and Fiorella Speziani and Justin Price and Taylor, {Sean W.} and Michel Melanson and Vance, {Jeffery M} and Zuchner, {Stephan L}",
year = "2011",
month = "7",
day = "1",
doi = "10.1007/s00415-011-5910-7",
language = "English",
volume = "258",
pages = "1234--1239",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "7",

}

TY - JOUR

T1 - Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2

AU - McCorquodale, Donald S.

AU - Montenegro, Gladys

AU - Peguero, Ainsley

AU - Carlson, Nicole

AU - Speziani, Fiorella

AU - Price, Justin

AU - Taylor, Sean W.

AU - Melanson, Michel

AU - Vance, Jeffery M

AU - Zuchner, Stephan L

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Charcot-Marie-Tooth (CMT) disease is among the most common inherited neurological disorders. Mutations in the gene mitofusin 2 (MFN2) cause the axonal subtype CMT2A, which has also been shown to be associated with optic atrophy, clinical signs of first motor neuron involvement, and early onset stroke. Mutations in MFN2 account for up to 20-30% of all axonal CMT type 2 cases. To further investigate the prevalence of MFN2 mutations and to add to the genotypic spectrum, we sequenced all exons of MFN2 in a cohort of 39 CMT2 patients. We identified seven variants, four of which are novel. One previously described change was co-inherited with a PMP22 duplication, which itself causes the demyelinating form CMT1A. Another mutation was a novel in frame deletion, which is a rare occurrence in the genotypic spectrum of MFN2 characterized mainly by missense mutations. Our results confirm a MFN2 mutation rate of ~15-20% in CMT2.

AB - Charcot-Marie-Tooth (CMT) disease is among the most common inherited neurological disorders. Mutations in the gene mitofusin 2 (MFN2) cause the axonal subtype CMT2A, which has also been shown to be associated with optic atrophy, clinical signs of first motor neuron involvement, and early onset stroke. Mutations in MFN2 account for up to 20-30% of all axonal CMT type 2 cases. To further investigate the prevalence of MFN2 mutations and to add to the genotypic spectrum, we sequenced all exons of MFN2 in a cohort of 39 CMT2 patients. We identified seven variants, four of which are novel. One previously described change was co-inherited with a PMP22 duplication, which itself causes the demyelinating form CMT1A. Another mutation was a novel in frame deletion, which is a rare occurrence in the genotypic spectrum of MFN2 characterized mainly by missense mutations. Our results confirm a MFN2 mutation rate of ~15-20% in CMT2.

KW - Charcot-Marie-Tooth disease

KW - CMT2

KW - CMT2A

KW - Inherited peripheral neuropathies

KW - MFN2

KW - Mitofusin 2

UR - http://www.scopus.com/inward/record.url?scp=79961020421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961020421&partnerID=8YFLogxK

U2 - 10.1007/s00415-011-5910-7

DO - 10.1007/s00415-011-5910-7

M3 - Article

C2 - 21258814

AN - SCOPUS:79961020421

VL - 258

SP - 1234

EP - 1239

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 7

ER -